GFAP and central nervous system cancer: Serum GFAP was significantly increased in WHO grade 4 glioma (GBM) and was detected in 63% of all grade 4 patients compared to 13% of healthy controls [31, 50], , suggesting that glioma patients have elevated plasma GFAP, in accordance with our findings.